Nanomedicine strategies for molecular targets with MRI and optical imaging

Future Medicinal Chemistry

Volumn 2, Issue 3, 2010, Pages 471-490

  Pan, Dipanjan ^a   Caruthers, Shelton D ^a   Chen, Junjie ^a   Winter, Patrick M ^a   Senpan, Angana ^a   Schmieder, Anne H ^a   Wickline, Samuel A ^a   Lanza, Gregory M ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBON; CONTRAST MEDIUM; CYANINE DYE; DENDRIMER; DOXORUBICIN; FERRIC HYDROXIDE; FERUMOXYTOL; FLUORESCEIN DERIVATIVE; FLUORINE; FLUORODEOXYGLUCOSE F 18; FUMAGILLIN; FUMAGILLOL CHLOROACETYLCARBAMATE; GADOLINIUM; GOLD NANOPARTICLE; IRON OXIDE; MANGANESE; MELITTIN; MONOCRYSTALLINE IRON OXIDE NANOPARTICLE; NANOPARTICLE; PACLITAXEL; POLYAMIDOAMINE; QUANTUM DOT; RAPAMYCIN; SUPERPARAMAGNETIC IRON OXIDE; VITRONECTIN RECEPTOR; XANTHENE DERIVATIVE;

ANGIOGENESIS; ATAXIA; CLINICAL TRIAL; CONTRAST ENHANCEMENT; DENDRITIC CELL; DIPLOPIA; DRUG DELIVERY SYSTEM; DRUG EXPOSURE; DRUG MECHANISM; FLUORINE NUCLEAR MAGNETIC RESONANCE; HUMAN; HYPOXIA; MOLECULAR IMAGING; MOLECULAR PROBE; MONOCYTE; NANOMEDICINE; NANOTECHNOLOGY; NEUROTOXICITY; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; NYSTAGMUS; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; STEM CELL; WEAKNESS;

ANIMALS; DIAGNOSTIC IMAGING; DRUG DELIVERY SYSTEMS; FERRIC COMPOUNDS; HUMANS; INDIVIDUALIZED MEDICINE; MAGNETIC RESONANCE IMAGING; MAGNETICS; MOLECULAR STRUCTURE; NANOMEDICINE; NANOPARTICLES; QUANTUM DOTS;

EID: 77953373956     PISSN: 17568919     EISSN: None     Source Type: Journal    
DOI: 10.4155/fmc.10.5     Document Type: Review

References (213)

1. Soman N, Lanza G, Heuser J, Schlesinger P, Wickline S. Synthesis and characterization of stable fluorocarbon nanostructures as drug delivery vehicles for cytolytic peptides. Nano. Lett. 8, 1131-1136(2008).
2. Lanza GM, Yu X, Winter PMi et al. Targeted antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 106, 2842-2847 (2002).
3. Crowder KC, Hughes MS, Marsh JN et al. Sonic activation of molecularly-targeted nanoparticles accelerates transmembrane lipid delivery to cancer cells through contact-mediated mechanisms: implications for enhanced local drug delivery. Ultrasound Med. Biol. 31, 1693-1700 (2005).
4. 3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits. FASEB J. 22, 2758-2767 (2008).
5. Liang HD, Blomley MJK. The role of ultrasound in molecular imaging. Brit. J. Radiol. 76, S140-S150 (2003).
6. Kumar S, Kortum RR. Optical molecular imaging agents for cancer diagnostics and therapeutics. Nanomedicine 1(1), 23-30 (2006).
7. Ametamey SM, Honer MI, Schubiger PA. Molecular imaging with PET. Chem. Rev. 108(5), 1501-1516 (2008).
8. Rabin O, Manuel PJ, Grimm J, Wojtkiewicz G, Weissleder R. Nat. Mater. 5(2) 118-122 (2006).
9. Pan D, Williams TA, Senpan A et al. Detecting vascular biosignatures with a colloidal, radio-opaque polymeric nanoparticle. J. Am. Chem. Soc. 131(42), 15522-15527 (2009).
10. Nelson KL, Runge VM. Basic principles of MR contrast. Magn. Reson. Imaging 7, 124-136 (1995).
11. Sosnovik DE, Weissleder R. Emerging concepts in molecular MRI. Curr. Opin. Biotechnol. 18(1), 4-10(2007).
12. 13C. Brit. J. Radiol. 76, S118-S127, (2003).
13. Ross BD, Bhattacharya P, Wagner S, Tran T, Sailasuta N. Hyperpolarized MR imaging: neurologic applications of hyperpolarized metabolism. Am. J. Neuroradiol. 1, 24-33(2009).
14. Fain SB, Korosec FR, Holmes JH, O'Halloran R, Sorkness RL, Grist TM. Functional lung imaging using hyperpolarized gas MRL J. Magn. Reson. Imaging25(5), 910-923 (2007)
15. Winter P, Caruthers S, Yu X, et al. Improved molecular imaging contrast agent for detection of human thrombus. Mag. Reson. Med. 50, 411-416(2003).
16. Winter P, Athey P, Kiefer G et al. Improved paramagnetic chelate for molecular imaging with MiRL J. Magn. Magn. Mater. 293 540-545 (2005).
17. 3-targeted magnetic resonance imaging. Nat Med. 4, 623-626 (1998).
18. Lanza G, Lorenz C, Fischer S et al. Enhanced detection of thrombi with a. novel fibrintargeted magnetic resonance imaging agent. Acad. Radiol. 5(Suppl. 1), S173-S176 (1998).
19. Botnar RM, Buecker A, Wiethoff AJ et al. In vivo magnetic resonance imaging of coronary thrombosis using a fibrin-binding molecular magnetic resonance contrast agent. Circulation 110, 1463-1466 (2004).
20. Mulder WJ, Strijkers GJ, Habets JW et al. MR molecular imaging and fluorescence microscopy for identification of activated tumor endothelium using a bimodal lipidie nanoparticle. FASEB J. 19, 2008-2010 (2005).
21. Mulder WJ, Strijkers GJ, van Tilborg GA, Griffioen AW, Nicolay K. Lipid-based nanoparticles for contrast-enhanced MRI and molecular imaging. NMR Biomed. 19, 142-164 (2006).
22. Mulder WJ, van der Schaft DW, Hautvast PA et al. Early in vivo assessment of angiostatic therapy efficacy by molecular MRI. FASEBJ. 21, 378-383 (2007).
23. Frias JC, Williams KJ, Fisher EA, Fayad ZA. Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J. Am. Chem. Soc. 126, 16316-16317(2004).
24. Lipinski MJ, Amirbekian V, Frias JC et al. MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med. 56, 601-610 (2006).
25. Flacke S, Fischer S, Scott MI, et al. A novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation 104, 1280-1285 (2001).
26. 3 ß integrin-targeted nanoparticles. Circulation. 108, 2270-2274 (2003).
27. 3-integrin targeted fumagi.ll.in nanoparticles inhibit angiogenesis in atherosclerosis. Arterioscler. Tkromb. Vase. Biol. 26, 2103-2109 (2006).
28. Winter P, Caruthers S, Zhang H, Williams T, Wickline S, Lanza G. Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis. J. Am. Coll. Cardiol. Img. 1, 624-634 (2008).
29. 3targeted nanoparticle and. 1.5 tesla magnetic resonance imaging. Cancer Res. 63, 5838-5843 (2003).
30. 3-targeted paramagnetic nanoparticles. Magn Reson Med. 53, 621-627 (2005).
31. Schmieder AH, Caruthers SD, Zhang H et al. Three-dimensional MR mapping of angiogenesis with {α}5{β;}l({α}{v} {ß}3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model. FASEB J. 22, 4179-4189 (2008).
32. Morawski AM, Winter PM, Crowder KC et al. Targeted nanoparticles for quantitative imaging of sparse molecular epitopes with MRI. Magn Reson Med. 51(3), 480-486 (2004).
33. Bulte JW, Douglas T, Witwer B et al. Magnetodendrimers allow endosomal magnetic labeling and in vivo tracking of stem cells. Nat Biotechnol. 19, 1141-1147 (2001).
34. Wiener E, Konda S, Shadron A, Brechbiel M, Gansow O. Targeting dendrimer-chelates to tumors and tumor cells expressing the high-affinity folate receptor. Invest. Radiol. 32, 748-754(1997).
35. Kukowska-Latallo JF, Candido KA, Cao Z et al. Nanoparticle targeting of anticancer drug improves therapeutic response in animal, model of human epithelial cancer. Cancer Res. 65, 5317-5324 (2005).
36. Shi X, Thomas TP, Myc LA, Kotlyar A, Baker JR Jr. Synthesis, characterization, and intracellular uptake of carboxyl-terminated poly(amidoamine) dendrimer-stabilized iron oxide nanoparticles. Phys. Chem. Chem. Phys. 9, 5712-5720 (2007).
37. Landmark KJ, Dimaggio S, Ward J et al. Synthesis, characterization, and in vitro testing of superparamagnetic iron oxide nanoparticles targeted, using folic acidconjugated dendrimers. ACS Nano. 2, 773-783 (2008).
38. Shi X, Wang S, Meshinchi S et al. Dendrimer-entrapped gold nanoparticles as a platform, for cancer-cell targeting and imaging. Small. 3, 1245-1252 (2007).
39. Swanson SD, Kukowska-Latallo JF, Patri AK, et al. Targeted gadolinium-loaded dendrimer nanoparticles for tumor-specific magnetic resonance contrast: enhancement. Int. J. Nanomedicine3, 201-210 (2008).
40. Thomas TP, Shukla R, Kotlyar A et al. Dendrimer-epidermal growth factor conjugate displays superagonist activity. Biomacromolecules.9, 603-609 (2008)
41. Cheresh DA. Integrins in thrombosis, wound healing and cancer. Biochem. Soc. Trans. 19, 835-838 (1991).
42. 5 in ocular neovascular diseases. Proc. Natl Acad. Sci. USA 93, 9764-9769 (1996).
43. De Nichilo MI, Burns G. Granulocytemacrophage and macrophage colonystimulating factors differentially regulate a v integrin expression on cultured human macrophages Proc. Natl Acad. Sci. USA 90, 2517-2521 (1993).
44. Helluin O, Chan C, Vilaire G, Mousa S, DeGrado WF, Bennett JS. The activation state of αvβ 3 regulates platelet and lymphocyte adhesion to intact and. thrombin-cleaved osteopontin. J. Biol. Chem. 275, 18337-18343 (2000).
45. Itoh H, Nelson P, Mureebe L, Horowitz A, Kent K. The role of integrins in saphenous vein vascular smooth muscle cell migration. J. Vase. Surg. 25, 1061-1069 (1997).
46. Carreiras F, Denoux Y, Staedel C, Lehmann M, Sichel F, Gauduchon P. Expression and localization of a v integrins and their ligand vitronectin in normal ovarian epithelium and in ovarian carcinoma. Gynecol. Oncol. 62, 260-267 (1996).
47. Kageshita T, Hamby CV, Hirai S, Kimura T, Ono T, Ferrone S. Differential clinical significance of α(v)B(3) expression in primary lesions of acral lentiginous melanoma and. of other melanoma histotypes. Int. J. Cancer. 89, 153-159 (2000).
48. 3-integrintargeted 111 In nanoparticles. Int. J. Cancer. 120, 1951-1957(2007).
49. Weissleder R, Bogdanov A Jr, Tung CH, Weinmann HJ. Size optimization of synthetic graft copolymers for in vivo angiogenesis imaging. Bioconjug Chem. 12, 213-219 (2001).
50. Zetter BR. Angiogenesis and tumor metastasis. Annu. Rev. Med. 49, 407-424 (1998).
51. Folkman J. Tumor angiogenesis. Adv. Cancer Res. 43, 175-203 (1985).
52. Carmeliet P. Mechanisms of angiogenesis andarteriogenesis. Nat: Med. 6, 389-395 (2000).
53. Lanza GM, Yu X, Winter PM et al. Targeted, antiproliferative drug delivery to vascular smooth muscle cells with a magnetic resonance imaging nanoparticle contrast agent: implications for rational therapy of restenosis. Circulation 106, 2842-2847 (2002).
54. Marsh J, Senpari A, Hu G, Scott M, Gaffney P, Wickline S, Lanza G. Fibrin-targeted perfluorocarbon nanoparticles for targeted thrombolysis. Nanomedicine 2, 533-543 (2007).
55. Cyrus T, Zhang H, Allen JS et al. Intramural delivery of rapamycin with αvβ3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury. Arterioscler. Thromb. Vase. Biol. 28, 820-826 (2008).
56. Partlow K, Lanza G, Wickline S. Exploiting lipid raft transport with membrane targeted nanoparticles: a strategy for cytosolic drug delivery. Biomaterials 29, 3367-3375 (2008).
57. Liu S, Widom J, Kemp CW, Crews CM, Clardy J. Structure of human methionine aminopeptidase-2 complexed with fumagillin. Science. 282, 1324-1327 (1998).
58. Sin N, Meng L, Wang MQ, Wen JJ, Bornmann WG, Crews CM. The antiangiogenic agent fumagillin covalently binds and inhibits the methionine aminopeptidase, MetAP-2. Proc. NatlAcad. Sci, USA 94, 6099-6103 (1997).
59. Bergers G, Javaherian K, Lo KM, Folkman J, Hanahan D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science. 284, 808-812 (1999).
60. Castronovo V, Belotti D. TNP-470 (AGM-1470), mechanisms of action and early clinical development. Eur. J. Cancer. 32A, 2520-2527 (1996).
61. Koririo H, Tanaka T, Kanai T, Maruyama K, Nakamura S, Baba S. Efficacy of an angiogenesis inhibitor, TNP-470, in xenotransplanted human colorectal cancer with high metastatic potential. Cancer 77, 1736-1740 (1996).
62. Shusterman S, Grupp SA, Barr R, Carpentieri D, Zhao H, Maris JM. The angiogenesis inhibitor TNP-470 effectively inhibits human neuroblastoma xenograft growth, especially in the setting of subclinical disease. Clin. Cancer Res. 7, 977-984 (2001).
63. Bhargava P, Marshall JL, Rizvi N et al. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin. Cancer Res. 5, 1989-1995 (1999).
64. Kudelka AP, Verschraegen CF, Loyer E. Complete remission of metastatic cervical cancer with the angiogenesis inhibitor TNP-470. N Engl. J Med, 338, 991-992 (1998).
65. Kudelka AP, Levy T, Verschraegen CF et al. A phase I study of TNP-470 administered to patients with advanced squamous cell cancer of the cervix. Clin. Cancer Res. 3, 1501-1505 (1997).
66. Logothetis CJ, Wu KK, Finn LD et al. Phase I trial, of the angiogenesis inhibitor TNP-470 for progressive androgen-independent prostate cancer. Clin. Cancer Res. 7, 1198-1203 (2001).
67. Offodile R, Walton T, Lee MI, Stiles A, Nguyen M. Regression of metastatic breast cancer in a patient treated with the antiangiogenic drug TNP-470. Tumori. 85, 51-53 (1999).
68. Bachert P. Pharmacokinetics using fluorine NMR in vivo. Prog. Nucl. Magn. Reson. Spectrosc. 33, 1-56 (1998).
69. WoIf W, Presant CA, Waluch V. 19F-MRS studies of fluorinated drugs in humans. Adv. Drug Deliv. Rev. 41, 55-74 (2000).
70. Kaneda MM, Caruthers S, Lanza GM, Wickline SA. Perfluorocarbon nanoemulsions for quantitative molecular imaging and targeted therapeutics. Ann. Biomed. Eng 37, 1922-1933 (2009).
71. Mason RP, Hunjan S, Le D et al. Regional tumor oxygen tension: fluorine echo planar imaging of hexafluorobenzene reveals heterogeneity of dynamics. Int. J. Radiat Oncol. Biol. Phys. 42, 747-750 (1998).
72. Davda S, Bezabeh T Advances in methods for assessing tumor hypoxia in vivo: implications for treatment planning. Cancer Metastasis Rev. 25, 469-480 (2006).
73. 2 measurements. Biomater. Artif Cells Immobilization Biotechnol. 19, 435 (1991).
74. 2 measurements. Biomater. Artif Cells Immobilization Biotechnol. 20, 917-920 (1992).
75. Spiess BD. Perfluorocarbon emulsions as a promising technology: a review of tissue and vascular gas dynamics. J. Appl. Physiol. 106, 1444-1452 (2009).
76. Barrett T, Brechbiel M, Bernardo M, Choyke PL. MRI of tumor angiogenesis. J. Magn. Reson. Imaging. 26, 235-249 (2007).
77. Iannetti GD, Wise RG. BOLD functional MRI in disease and pharmacological studies: room for improvement? Magn. Reson. Imaging. 25, 978-988 (2007).
78. Matthews PM, Jezzard P. Functional magnetic resonance imaging. J Neurol. Neurosurg. Psychiatry. 75, 6-12 (2004).
79. Merboldt KD, Fransson P, Bruhri H, Frahm J. Functional MRI of the human amygdala? Neurolmage 14, 253-257 (2001 (Pubitemid 32709541)
80. Padhani AR, Krohri KA, Lewis JS, Alber M. Imaging oxygenation of human tumours. Eur. Radiol. 17, 861-872 (2007).
81. Vaupel P, Mayer A. Hypoxia in cancer: Significance and impact on clinical outcome. Cancer Metastasis Rev. 26, 225-239 (2007).
82. Kodibagkar VD, Wang X, Mason RP. Physical principles of quantitative nuclear magnetic resonance oximetry. Front. Biosci. 13, 1371-1384 (2008).
83. Zhao D, Constantinescu A, Hahn EW, Mason RP. Tumor oxygen dynamics with respect to growth and. respiratory challenge: investigation of the Dunning prostate R3327-HI tumor. Radiat. Res. 156, 510-520 (2001).
84. Mason RP, Constantinescu A, Hunjan S et al. Regional tumor oxygenation and measurement of dynamic changes. Radiat. Res. 152,239-249(1999).
85. Hunjan S, Zhao D, Canstaridtinescu A, Hahan E, Antich P, Mason R. Tumor oximetry: demonstration of an enhanced dynamic mapping procedure using fluorine-19 echo planar magnetic resonance imaging the Dunning prostate R3327-Atl rat tumor. Int. J. Radiat. Oncol. Biol. Phys. 49, 1097-1108 (2001).
86. Lanza GM, Wallace KD, Scott MJ et al. A novel site-targeted ultrasonic contrast: agent with broad biomedical application. Circulation. 95, 3334-3340 (1996).
87. 19F MiR imaging with a novel, fibrintargeted nanoparticulate contrast agent. Proc. Intl. Sot: Mag. Reson. Med. 8, 465 (2000).
88. Morawski AMi, Winter PM, Yu X et al. Quantitative "magnetic resonance immun oh istoche mistry" with ligand-targeted (19) F nanoparticles. Magn. Reson. Med. 52, 1255-1262 (2004).
89. 19F magnetic resonance to augment molecular imaging with paramagnetic perfluorocarbon nanoparticles at 1.5 Tesla. Invest Radiol. 41, 305-312 (2006).
90. Neubauer AM, Caruthers SD, Hockett FD et al. Fluorine cardiovascular magnetic resonance angiography in vivo at 1.5 T with perfluorocarbon nanoparticle contrast agents. J. Cardiovasc. Magn. Reson. 9 565-573, (2007)
91. Witers EA, Chen J, Allen JS et al. Detection and quantification of angiogenesis in experimental valve disease with integrintargeted nanoparticles and 19-fluorine MRI/MiRS J. Cardiovasc. Magn. Reson. 10, 43 (2008).
92. 19F NMR of VCAM-1 targeted, nanobeacons. Nanomedicine 5, 359-367 (2009).
93. Waters EA, Chen J, Yang X et al. Detection of targeted perfluorocarbon nanoparticle binding using 19F diffusion weighted MR spectroscopy. Magn. Reson. Med. 60, 1232-1236 (2008).
94. Arbab AS, Yocum GT, Kalish H et al. Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood 104, 1217-1223 (2004).
95. Arbab AS, Jordan EK, Wilson LB, Yocum GT, Lewis BK, Frank JA. In vivo trafficking and targeted delivery of magnetically labeled stem cells. Hum. Gene Ther. 15, 351-360 (2004).
96. Modo M, Mellodew K, Cash D et al. Mapping transplanted stem cell migration after a stroke: a serial, in vivo magnetic resonance imaging study. Neuroimage 21, 311-317(2004).
97. Shapiro E, Sharer K, Skrtic S, Koretsky A. In vivo detection of single cells by MRI. Magn. Reson. Med. 55, 242-249 (2006).
98. Bulte JW Hot spot MRI emerges from the background. Nat: Biotechnol. 23, 945-946 (2005).
99. Ahrens ET, Flores R, Xu H, Morel. PA. In vivo imaging platform, for tracking immunotherapeutic cells. Nat. Biotechnol. 23, 983-987 (2005).
100. Partlow KC, Chen J, Brant JA et al. 19F magnetic resonance imaging for stem/ progenitor cell tracking with multiple unique perfluorocarbon nanobeacons. FASEB J. 21, 1647-1654 (2007).
101. Ruiz-Cabello J, Walczak P, Kedziorek D et al. In vivo "hot spot" MR imaging of neural stem cells using fluorinated nanoparticles. Magn. Reson. Med. 60, 1506-1511 (2008).
102. Srinivas M, Morel PA, Ernst LA, Laidlaw DH, Ahrens ET. Fluorine-19 MRI for visualization and quantification of cell migration in a diabetes model. Magn. Reson. Med. 58, 725-734 (2007).
103. Stark DD, Weissleder R, Elizondo G et al. Superparamagnetic iron oxide: clinical application as a contrast agent for MR imaging of the liver. Radiology 168, 297-301 (1988).
104. Weissleder R, Halm PF, Stark DD et al. Superparamagnetic iron oxide: enhanced detection of focal splenic tumors with MR imaging. Radiology 169, 399-403 (1988).
105. Frank H, Weissleder R, Brady TJ. Enhancement of MR angiography with iron oxide: preliminary studies in whole-blood phantom and in animals. AJR Am. J. Roentgenol. 162, 209-213 (1994).
106. Kresse M, Wagner S, Pfefferer D, Lawaczeck R, Elste V, Semmler W. Targeting of ultrasmall superparamagnetic iron oxide (USPIO) particles tumor cells in vivo by using transferrin receptor pathways. Magn. Reson. Med. 40, 236-242 (1998).
107. Jung C, Jacobs P. Physical and chemical properties of superparamagnetic iron oxide MR contrast agents: ferumoxides, Ferumoxtran, ferumoxsil. Magn. Reson. Imaging 13, 661-674 (1995).
108. Anzai Y, Prince MR, Chenevert TL et al. MR angiography with an ultrasmall superparamagnetic iron oxide blood pool agent. J. Magn. Reson. Imaging 7, 209-214 (1997).
109. Loubeyre P, Zhao S, Canet E, Abidi H, Benderbous S, Revel D. Ultrasmall superparamagnetic iron oxide particles (AMI 227) as a blood pool contrast agent for MR angiography: experimental study in rabbits. J. Magn. Reson. Imaging 7, 958-962 (1997).
110. Schellenberger EA, Bogdanov A Jr, Hogemann D, Tait J, Weissleder R, Josephson L. Annexin V-CLIO: a nanoparticle for detecting apoptosis by MRI. Mol. Imaging 1, 102-107 (2002).
111. Kircher MF, Allport JR, Graves EE et al. In vivo high resolution three-dimensional imaging of antigen-specific cytotoxic T-lymphocyte trafficking to tumors. Cancer Res. 63, 6838-6846 (2003).
112. Kelly KA, Allport JR, Tsourkas A, Shinde-Patil VR, Josephson L, Weissleder R. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ. Res. 96, 327-336 (2005).
113. Schmitz SA, Coupland SE, Gust R et al. Superparamagnetic iron oxide-enhanced MRI of atherosclerotic plaques in Watanabe hereditable hyperlipidemic rabbits. Invest. Radiol. 35, 460-471 (2000).
114. Schmitz SA, Taupitz M, Wagner S et al. Magnetic resonance imaging of atherosclerotic plaques using superparamagnetic iron oxide particles. J. Magn. Reson. Imaging 14, 355-361 (2001).
115. Schmitz S, Taupitz M, Wagner S et al. Iron-oxide-enhanced magnetic resonance imaging of atherosclerotic plaques: postmortem analysis of accuracy, inter-observer agreement, and pitfalls. Invest. Radiol. 37, 405-411 (2002).
116. Ruehm SG, Corot C, Vogt P, Kolb S, Debatin JF. Magnetic resonance imaging of atherosclerotic plaque with ultrasmall superparamagnetic particles of iron oxide in hyperlipidemic rabbits. Circulation 103, 415-422 (2001).
117. Kooi ME, Cappendijk VC, Cleutjens KB et al. Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation 107, 2453-2458 (2003).
118. Herborn CU, Vogt FM, Lauenstein TC et al. Magnetic resonance imaging of experimental atherosclerotic plaque: comparison of two ultrasmall superparamagnetic particles of iron oxide. J. Magn. Reson. Imaging 24, 388-393 (2006).
119. Cunningham C, Arai T, Yang P et al. Positive contrast magnetic resonance imaging of cells labeled with magnetic nanoparticles. Magn. Reson. Med. 53, 999-1005 (2005).
120. Dharmakumar R, Koktzoglou I, Li D. Generating positive contrast from off-resonant spins with steady-state free precession magnetic resonance imaging: Theory and proof-ofprinciple experiments. Phys. Med. Biol. 51, 4201-4215 (2006).
121. Mani V, Briley-Saebo KC, Itskovich VV, Sarnber DD, Fayad ZA. Gradient echo acquisition for superparamagnetic particles with positive contrast (GRASP), sequence characterization in membrane and glass superparamagnetic iron oxide phantoms at 15T and 3T. Magn. Reson. Med. 55, 126-135 (2006).
122. Zurkiya O, Hu X. Off-resonance saturation as a means of generating contrast with superparamagnetic nanoparticles. Magn. Reson. Med. 56, 726-732 (2006).
123. Stuber M, Gilson WD, Schar M et al. Positive contrast visualization of iron oxide-labeled stem cells using inversion-recovery with ONresonant water suppression (IRON). Magn. Reson. Med. 58, 1072-1077 (2007).
124. Korosoglou G, Tang L, Kedziorek D et al. Positive contrast MR-lymphography using inversion recovery with ON-resonant water suppression (IRON). J. Magn. Reson, Imaging. 27, 1175-1180 (2008).
125. Korosoglou G, Weiss RG, Kedziorek DA et al. Noninvasive detection of macrophage-rich atherosclerotic plaque in hyperlipidemic rabbits using "positive contrast" magnetic resonance imaging. J. Am. Coll. Cardiol. 52, 483-491 (2008).
126. Korosoglou G, Shah S, Vonken EJ et al. Off-resonance angiography: a new method to depict vessels - phantom and rabbit studies. Radiology. 249, 501-509 (2008).
127. Weissleder R, Moore A, Mahmood U et al. In vivo magnetic resonance imaging of transgene expression. Nat Med. 6, 351-355 (2000).
128. Dunn JF, Roche MA, Springett R et al. Monitoring angiogenesis in brain using steady-state quantification of δR2 with MION infusion. Magn. Reson, Med. 51, 55-61 (2004).
129. Hogemann D, Josephson L, Weissleder R, Basilion JP. Improvement of MRI probes to allow efficient detection of gene expression. Bioconjug. Chem. 11, 941-946 (2000).
130. Kang HW, Josephson L, Petrovsky A, Weissleder R, Bogdanov A Jr. Magnetic resonance imaging of inducible E-selectin expression in human endothelial cell culture. Bioconjug. Chem. 13, 122-127 (2002).
131. Koch AM, Reynolds F, Kircher MF, Merkle HP, Weissleder R, Josephson L. Uptake and metabolism of a dual fluorochrome Tat-nanoparticle in HeLa cells. Bioconjug. Chem. 14, 1115-1121 (2003).
132. Josephson L, Tung CH, Moore A, Weissleder R. High-efficiency intracellular magnetic labeling with novel superparamagnetic-Tat peptide conjugates. Bioconjug Chem. 10, 186-191 (1999).
133. Dodd CH, Hsu HC, Chu WJ et al. Normal T-cell response and in vivo magnetic resonance imaging of T cells loaded with HIV transactivator-peptide- derived superparamagnetic nanoparticles. J. Immunol. Methods. 256, 89-105 (2001).
134. Lewin M, Carlesso N, Tung CH et al. Tat peptide-derivatized magnetic nanoparticles allow in vivo tracking and recovery of progenitor cells. Nat. Biotech. 18, 410-414 (2000).
135. Nahrendorf M, Jaffer FA, Kelly KA et al. Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation 114, 1504-1511 (2006).
136. von zur Muhlen C, von Elverfeldt D, Moeller JA et al. Magnetic resonance imaging contrast agent targeted toward activated platelets allows in vivo detection of thrombosis and monitoring of thrombolysis. Circulation 118, 258-267 (2008).
137. McAteer MA, Schneider JE, Ali. ZA et al. Magnetic resonance imaging of endothelial adhesion molecules in mouse atherosclerosis using dual-targeted microparticles of iron oxide. Arterioscler. Thromb. Vase. Biol. 28, 77-83 (2008).
138. 2 weighted MRI. J. Cardiovasc. Magn. Reson. 10(Suppl.1), A384 (2008).
139. Senpan A, Caruthers S, Rhee I et al. Conquering the dark side: colloidal iron oxide nanoparticles. ACS Nano. 3(12), 3917-3926 (2009).
140. Lu J, Ma S, Sun J et al. Manganese ferrite nanoparticle micellar nanocomposites as MRI contrast agent for liver imaging. Biomaterials 30, 2919-2928 (2009).
141. Yang J, Lee CH, Ko HJ et al. Multifunctional magneto-polymeric nanohybrids for targeted detection and synergistic therapeutic effects on breast cancer. Angew Chem. Int. Ed. Engl. 46, 8836-8839 (2007).
142. Federle M, Chezmar J, Rubin DL et al. Efficacy and safety of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: results of the U.S. multicenter phase III clinical trials. Efficacy of early imaging. J. Magn. Reson. Imaging. 12, 689-701 (2000).
143. Federle MP, Chezmar JL, Rubin DL et al. Safety and efficacy of mangafodipir trisodium (MnDPDP) injection for hepatic MRI in adults: Results of the US multicenter phase III clinical trials (safety). J. Magn. Reson. Imaging 12, 186-197 (2000).
144. Aime S, Anelli PL, Botta M et al. Relaxometric evaluation of novel manganese (II) complexes for application as contrast agents in magnetic resonance imaging. J. Biol. Inorg. Chem. 7, 58-67 (2002).
145. Troughton JS, Greenfield MT, Greenwood. JM et al. Synthesis and evaluation of a high relaxivity manganese(II)-based MRI contrast agent. Inorg. Chem. A3, 6313-6323 (2004).
146. 1 contrast agent for magnetic resonance imaging using MnO nanoparticles. Angew Chem. Int. Ed. Engl. 46, 5397-5401 (2007).
147. Shin J, Anisur RM, Ko MK et al. Hollow manganese oxide nanoparticles as multifunctional agents for magnetic resonance imaging and drug delivery. Angew Chem. Int. Ed. Engl. 48, 321-324 (2009).
148. Pan D, Caruthers SD, Hu G et al. Liganddirected nanobialys as theranostic agent for drug delivery and manganese-based magnetic resonance imaging of vascular targets. J. Am. Chem, Soc. 130, 9186-9187 (2008).
149. Pan D, Senpan A, Caruthers SD et al. Sensitive and efficient detection of thrombus with fibrin-specific manganese nanocolloids. Chem. Commun. (Camb). 22, 3234 3236 (2009).
150. Ntziachristos V. Fluorescence molecular imaging. Ann. Rev. Biomed. Eng. 8, 1-33 (2009).
151. Zhang HF, Maslov K, Stoica G, Wing LV. Functional photoacoustic microscopy for highresolution and noninvasive in vivo imaging. Nat. Biotechnol. 24, 848-851 (2006).
152. Zhang HF, Maslov K, Wang LV. In vivo imaging of subcutaneous structures using functional photoacoustic microscopy. Nature Protocols 2, 797-804 (2007).
153. Frangioni JV. In vivo near-infrared fluorescence imaging. Curr. Opin. Chem. Biol. 5, 626-634 (2003).
154. Mahmood U, Weissleder R. Near-infrared optical imaging of proteases in cancer. Mol. Cancer Ther. 2(5), 489-496 (2003).
155. Michalet X, Pinaud FF, Bentolila LA et al. Quantum, dots for live cells, in vivo imaging, and diagnostics Science 307, 538-544 (2005).
156. Ya-Ping S, Bing Z, Yi L et al. Am. Chem. Soc., 128 (24), 7756-7757 (2006).
157. Kannan R, Katti KV. Targeted, gold nanoparticles for imaging and therapy biomedical applications of nanotechnology. Wiley, UK (2007).
158. Hama Y, Urano Y, Koyama Y, Choyke PL, Kobayashi H. Activatable fluorescent molecular imaging of peritoneal metastases following pretargetirig with a biotinylated monoclonal antibody. Cancer Res. 67(8), 3809-3817 (2007).
159. Griffin JMM, Skwierawska AM Manning HC, Marx JN, Bornhop DJ. Simple, high yielding synthesis of afunctional fluorescent lanthanide chelates Tetr. Lett: 42(23), 3823-3825 (2001).
160. Licha K, Hessenius C, Becker A et al. Synthesis, characterization, and biological properties of cyanine-labeled somatostatin analogues as receptor-targeted fluorescent probes. Bioconjug. Chem. 12(1), 44-50 (2001).
161. Chin WW, Thong PS, Bhuvaneswari R, Soo KC, Heng PW, Olivo M. In vivo optical detection of cancer using chlorin e6polyvinylpyrrolidone induced fluorescence imaging and spectroscopy. BMC Med. Imaging 9, 1 (2009).
162. Bailou B, Lagerholm BC, Ernst LA, Bruchez MP, Waggoner AS. Noninvasive imaging of quantum dots in mice. Bioconjug. Chem. 15, 79-86 (2004).
163. Kim S et al. Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat. Biotechnol. 22, 93-95 (2004).
164. Akerman ME, Chan WCW, Laakkonen P, Bhatia SN, Ruoslahti E. Nanocrystal targeting in vivo. Proc. Natl Acad. Sci. USA 99, 12617-12621 (2002).
165. Bailou B, Lagerholm BC, Ernst LA, Bruchez MP, Waggoner AS. Noninvasive imaging of quantum dots in mice. Bioconjug. Chem. 15, 79-86 (2004).
166. Cai W, Shin DW, Chen K et al. Persistent tissue kinetics and redistribution of nanoparticles, quantum dot 705, in mice: ICP-MS quantitative assessment. Nano Lett. 6, 669-676 (2006).
167. Dahan M et al. Diffusion dynamics of glycine receptors revealed by single-quantum dot tracking. Science 302, 442-445 (2003).
168. Lidke DS. Quantum, dot ligands provide new insights into erbB/HER receptor-mediated signal transduction. Nat. Biotechnol. 22, 198-203 (2004).
169. Ness JM, Akhtar RS, Latham CB, Roth KA. Combined tyramide signal amplification and quantum dots for sensitive and photostable immunofluorescence detection. J. Histochem. Cytochem. 51, 981-987 (2003).
170. Xiaohu G, Yuanyuan C, Richard ML, Leland W, Shuming N. In vivo cancer targeting and imaging with semiconductor quantum dots. Nat. Biotechnol. 22, 969-976 (2004).
171. Yu X, Chen L, Li K et al. Immunofluorescence detection with quantum dot bioconjugates for hepatoma in vivo. J. Biomed. Opt. 12, 014008 (2007).
172. Sungjee K, Yong TL, Edward GS et al: Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat. Biotechnol. 22(1), 93-97 (2004).
173. Lovric J. Unmodified cadmium telluride quantum, dots induce reactive oxygen. Chem. Biol. 12, 1227-1234 (2005).
174. Choi HS, Ipe BI, Misra P et al. Tissue- and organ-selective biodistribution of NIR fluorescent quantum dots. Nano. Lett. 9(6), 2354-2359 (2009).
175. Allen PM, Bawendi MG. Ternary I-III-VI quantum dots luminescent in the red to near-infrared. J. Am. Chem. Soc. 130(29), 9240-9241 (2008).
176. Sheng-Tao Y, Li C, Pengju G et al. Carbon dots for multiphoton bioimaging. Am. Chem. Soc. 131(32), 11308-11309 (2009).
177. Ray SC, Saha A, Jana NR, Sarkar R. Fluorescent carbon nanoparticles: synthesis, characterization, and bioimaging application. J. Phys. Chem. C 113, 18546-18551 (2009).
178. Achilefu S, Jimenez HN, Dorshow RB et al. Synthesis, in vitro receptor binding, and in vivo evaluation of fluorescein and carbocyanine peptide-based optical contrast agents. J. Med. Chem. 45, (2003)-2015 (2002).
179. Folli S, Wagnieres G, Pelegrin A et al. Immunophotodiagnosis of colon carcinomas in patients injected with fluoresceinated chimeric antibodies against carcinoembryonic antigen. Proc. Natl Acad. Sci. USA 89, 7973-7977 (1992).
180. Williams DJ. Organic polymeric and non polymeric materials with large optical non linearities. Angew. Chem. Int. Ed. Engl. 23, 690-703 (1984).
181. Gomez-Hens A, Aguilar-Caballos MP. Long-wavelength fluorophores new trends in their analytical use. Trends Anal. Chem. 23, 127 (2004).
182. Patonay G, Salon J, Sowell J, Strekowski L. noncovalent labeling of biomolecul.es with red and near- infrared dyes. Molecules 9, 40-49 (2004).
183. Tung C-H. Fluorescent peptide probes for in vivo diagnostic imaging Biopolymers 76, 391-403 (2004).
184. Weissleder R, Ntziachristos V. Shedding light onto live molecular targets. Nat. Med. 9, 123-128 (2003).
185. Mason SJ, Balasubramanian S. Solid-phase catch, activate, arid release synthesis of cyanine dyes. Org. Lett. 4, 4261-4264 (2002).
186. Mason SJ, Hake JL, Nairne J, Cummins WJ, Balasubramanian SJ. Solid-phase methods for the synthesis of cyanine dyes. J. Org. Chem. 70, 2939-2949 (2005).
187. PengX, Song F, Lu E et al. Heptamethine cyanine dyes with a large stokes shift and strong fluorescence: a paradigm for excitedstate intramolecular charge transfer. J. Am. Chem. Soc. 127, 4170 (2005).
188. Song F, PengX, Lu E, Wang Y, Zhou W, Fan J. Tuning the photoinduced electron transfer in near-infrared heptamethine cyanine dyes Tetrahedron Lett. 46, 4817 (2005).
189. Gruber HJ, Hahn CD, Kada G et al. Anomalous fluorescence enhancement of cy3 and cy3.5 versus anomalous fluorescence loss of cy5 and cy7 upon covalent linking to proteins and noncovalent binding to avidin. Bioconj. Chem. 11, 696-704 (2000).
190. Kelly KA, Allport JR, Tsourkas A et al. Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ. Res. 96, 327-336 (2005).
191. Tung CH, Quinti L, Jaffer FA et al. A branched fluorescent peptide probe for imaging of activated platelets. Mol. Pharm. 2(1), 92-95 (2005).
192. Hilderbrand SA, Kelly KA, Weissleder R et al. Monofunctional near-infrared fluorochromes for imaging applications Bioconj. Chem. 16, 1275-1281 (2005).
193. Kai L, Bjorn R, Vasilis N et al. Hydrophilic cyanine dyes as contrast agents for near-infrared tumor imaging: synthesis, photophysical properties and spectroscopic in vivo characterization. Photochem. Photobiol, 72(3), 392-398 (2000).
194. Bouteiller C, Clave G, Bernardin A et al. Near-infrared fluorescent pH-sensitive probes via unexpected barbituric acid mediated synthesis. Bioconj. Chem. 18, 1303-1317(2007).
195. Hilderbrand SA, Weissleder R. Nearinfrared fluorescence: application to in vivo molecular imaging. Curr Opin Chem Biol. 14(1)71-79(2009).
196. Mahmood U, Weissleder R. Near-infrared optical imaging of proteases in cancer molecular cancer therapeutics. Mol. Cancer Ther. 2, 489-496 (2003).
197. Wang LV. Prospects of photoacoustic tomography. Med. Phys. 35 (12), 5758-5767 (2008).
198. Maslov K, Zhang HF, Hu S, Wang LV. Optical-resolution photoacoustic microscopy for in vivo imaging of single capillaries. Opt. Lett. 33, 929-931 (2008).
199. Fang H, Maslov K, Wang LV. Photoacoustic Doppler effect from flowing small light-absorbing particles. Phys. Rev. Lett. 99, 184501 (2007).
200. Bruchez M Jr, Moronne M, Gin P et al. Semiconductor rianocrystals as fluorescent biological labels. Science 281, 2013-2016 (1998).
201. Chan WC, Maxwell DJ, Gao X et al. Luminescent quantum dots for multiplexed biological detection and imaging. Curr. Opin. Biotechnol. 13, 40-46 (2002).
202. Sharma P, Brown S, Walter G et al. Nanoparticles for bioimaging. Adv. Colloid Interface Sci. 123-126, 471-485 (2006).
203. Turkevich J, Stevenson PC, Hillier J. A study of the nucleation and growth process in the synthesis of colloidal gold. Discuss Faraday Soc. 11, 55-75(1951).
204. Kreibig U, Genzel L. Optical absorption of small metallic particles. Surf. Sci. 156, 678-700, (1985).
205. Khlebtsov NG, Trachuk LA, Mel'nikov AG. The effect of the size, shape, and structure of metal nanoparticles on the dependence of their optical properties on the refractive index of a disperse medium. Opt. Spectrosc. 98, 83-90 (2005).
206. Sarkar D, Halas NJ. General vector basis function solution of Maxwell's equations. Phys. Rev. E 56, 1102 (1997).
207. Jin RC, Cao YW, Mirkin CA. et al. Photoinduced conversion of silver nanospheres to nanoprisms. Science 294, 1901-1903 (2001).
208. Murphy CJ, Jana NR. Controlling the aspect ratio of inorganic nanorods and nanowires. Adv. Mater. 14, 80-82 (2002).
209. Marinakos SM, Novak JP, Brousseau LC et al. Gold particles as templates for the synthesis of hollow polymer capsules. Control of capsule dimensions and guest encapsulation. J. Am. Chem. Soc. 121, 8518-8522(1999).
210. Caruso RA, Antonietti M. Sol-gel nanocoating: an approach to the preparation of structured materials. Chem. Mater. 13, 3272-3282 (2001).
211. Agarwal A, Huang SW, O'Donnell M et al. Targeted, gold nanorod contrast agent for prostate cancer detection by photoacoustic imaging. J. Appl. Phys. 102, 064701 (2007).
212. Pan D, Pramanik M, Senpan A et al. Molecular photoacoustic tomography with colloidal nanobeacons. Angew Chem. Int. Ed. Engl. 48(23), 4170-4173 (2009).
213. Kim JW, Galanzha EI, Shashkov EV, Moon HM, Zharov VP. Golden carbon nanotubes as multimodal photoacoustic and photothermal high-contrast molecular agents. Nat. Nanotechnol. 10, 688-694 (2009).